Cancer therapy has become increasingly personalized. Biomarker-driven treatment selection, targeted therapies and immunotherapy have transformed outcomes across many tumor types, demonstrating the power of matching the right treatment to the right patient.
Yet even as precision medicine advances, a fundamental challenge remains. Many of our most successful strategies for improving outcomes rely on adding therapies, intensifying treatment or combining agents. One drug becomes two. Two drugs become three. While this approach has helped patients, it has also increased the complexity and toxicity of cancer care.
The microbiome is intriguing because it may offer a different approach — one that improves treatment outcomes without substantially increasing the burden of therapy.
Using the Microbiome to Influence Outcomes
The relationship between the microbiome and cancer outcomes is no longer a novel concept. Decades of research in transplantation, cellular therapy and oncology have demonstrated that microbial communities influence clinical outcomes. Foundational research helped establish these relationships in transplantation, while subsequent studies expanded our understanding in cellular therapy and cancer.
Much of the work over the past decade has focused on understanding how the microbiome affects clinical outcomes. The next step is determining whether we can deliberately use the microbiome itself to influence those outcomes.
From Early Research to Phase III Testing
At City of Hope, our research group has spent years studying CBM 588, an oral live bacterial product, in patients with advanced kidney cancer receiving immunotherapy. Two consecutive studies published in Nature Medicine evaluated immunotherapy with or without CBM 588. The studies demonstrated encouraging signals in progression-free survival, response rates and overall outcomes.
These findings raise an important question: Does modifying the microbiome improve the effectiveness of cancer treatment without substantially increasing toxicity?
The next step is testing that hypothesis in larger studies.
The launch of SWOG 2419 provides an opportunity to determine whether microbiome manipulation can meaningfully improve outcomes in a large patient population. The trial will evaluate the addition of CBM 588, now known as M003, to standard immunotherapy. It represents the first Phase III evaluation of a live bacterial product in cancer therapy.
The significance of the trial extends beyond a single product. It is an opportunity to determine whether the microbiome can become a therapeutic platform in oncology.
Rethinking Cancer Drug Development
The path from investigator-initiated research to a national Phase III trial also reflects changes in how oncology research is conducted.
Historically, promising therapies advanced through a rigid sequence of clinical development. Increasingly, investigators are moving from strong early-phase data into definitive trials more directly. This shift reflects the need to answer important questions more quickly, as well as recognition that intermediate studies do not always provide definitive answers and can sometimes delay the evaluation of promising therapies.
Thoughtfully designed early-phase studies remain essential, however. Many of the design features incorporated into SWOG 2419 originated in earlier investigator-initiated studies at City of Hope. This work established the scientific rationale for advancing the approach into definitive testing.
Collaboration is Essential to Progress
A successful Phase III study begins long before the trial itself.
Progress depends on translational scientists, clinical investigators, cooperative groups and research networks working together. It also depends on mentorship and the contributions of early-career researchers. Much of the early work supporting CBM 588 was conducted by then-City of Hope postdoctoral fellows, including Nazli Dizman and Hedyeh Ibrahimi. Their contributions helped build the evidence that ultimately led to SWOG 2419.
These collaborations are essential because the questions we seek to answer are becoming increasingly complex. Progress will require not only new drugs but also new ways of thinking about how we improve cancer treatment outcomes.
Looking Ahead
The potential of microbiome research lies in the possibility of improving treatment efficacy without substantially increasing toxicity. That hypothesis still requires definitive testing, but it has the potential to reshape how we approach cancer treatment development.
If successful, microbiome-based therapeutics could represent a new mechanism for improving outcomes — one that does not depend on simply adding more treatment. Whether that promise can be realized is precisely the question SWOG 2419 is designed to answer.
Dr. Pal is a medical oncologist and co-director of the Kidney Cancer Program at City of Hope; professor in the Department of Medical Oncology & Therapeutics Research at Beckman Research Institute of City of Hope; and clinical trials medical director at City of Hope Comprehensive Cancer Center.